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Background: Residual platelet reactivity (RPR) has been shown to be
related to adverse cardiovascular events. However, assessment of residual pla-
telet reactivity was often evaluated in heterogeneous populations including
both patients with stable disease and acute coronary syndrome.
Objectives: We aim to delineate determinants of RPR in a cohort of stable
cardiovascular patients.
Methods: We included 750 stable cardiovascular patients treated for at least
one month with aspirin (n=213), clopidogrel (n=107) or both (n=425). We eva-
luated RPR using collagen platelet aggregation (CPA), collagen being a stimulus
not directly involved in the specific pathways of aspirin and clopidogrel.
Results: Mean age was 65±12 years, 76% were male; the mean duration of
the CV disease was 1.6 years. CPA ranged from 6% to 96% in our population.
CPA was of 41+/-16, 61+/-14 and 28+/-15% in aspirin, clopidogrel and dual
treatment groups, respectively (P<0.001). In univariate analysis of relevant
biological and clinical parameters, antiplatelet drug treatment pattern
(P<0.001), diabetes (P=0.006), hypertension (P=0.01) and a pain-free walking
distance < 200m (P=0.02) were associated with CPA. Multivariate analysis
showed that antiplatelet drug treatment pattern (P<0.0001) and diabetes
(P=0.0007) were independent factors associated with CPA.
Conclusion: Aspirin had a more pronounced effect on CPA than clopido-
grel in stable cardiovascular patients. Even after adjustment for antiplatelet
drug pattern, diabetes remains an independent factor associated with CPA.
These results give new insight into the controversy about the beneficial effect
of antiplatelet drugs in this particular group of patients
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Thyroid hormones, cortisol and insulin affect the metabolism of myocardial
cells. Their secretion can be altered in case of ST elevation acute myocardial
infarction (STEMI) and their prognostic value is not well established.
The aim of this study was evaluate the hormonal profile and its correlation
with patient’s outcome in STEMI.
Methods and results: 186 consecutive patients (162 males, 87%) with
STEMI were prospectively enrolled. Blood sampling for insulin, cortisol, thyreos-
timulin (TSH), free thyroxin (FT4), triiodothyronin (T3) and free triiodothyronin
(FT3) level measurements were performed in the 24 hours after admission.
Patients who died within the first 24 hours were excluded. Mean follow-up period
was 17,2 [12-28.8] months. We distinguished 2 groups, with (MACE1+) and
without (MACE1-) in-hospital complications (Death and/or shock and/or left ven-
tricular insufficiency and/or myocardial infarction and/or revascularization) and 2
groups, with (MACE2+) or without (MACE2-) late complications (Death and/or
cardiac insufficiency and/or myocardial infarction and/or revascularization).The
mean age of patients was 58.4 ± 12.6 years. 77.9% were smokers, 35.4% were dia-
betics, 37% were hypertensive, 18.8% had a dyslipemia, 17.2% had a history of
familial coronary disease and 4.3% of patients had a renal insufficiency. Hormonal
levels were as follows: insulin=12.6±20.5 mU/l, cortisol=250.4±37 ng/ml,
TSH=2.3±8.3μU/l, FT4=10.2±3 ng/l, T3=0.83±0.23 pg/l, FT3=2.04±3ng/l. Diffe-
rences in hormonal levels between MACE1+ and MACE1- groups were signifi-
cant for cortisol (289.5±304.9 vs 217.5±110.2 ng/l, p=0.033) and T3 (0.83±0.23 vs
0.77±0.2 pg/l, p=0.001). Threshold values determined by ROC curves were 380
ng/l for the cortisol and 0.95 pg/l for T3. In a multivariate model, only T3 was
independently correlated with in-hospital outcome (OR=3.9, IC [1.6-9.8]). There
was no correlation between hormonal levels and late outcome.
In Conclusion: T3 affect short but not long term STEMI prognosis. The
usefulness of routine hormonal measurement and the therapeutic implications
are still to determine. 
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Purpose: To describe antiplatelet treatment patterns over 12 months in
patients with acute cornary syndrome (ACS) undergoing percutaneous coro-
nary intervention (PCI).
Methods: The AntiPlatelet Treatment Observational Registry (APTOR) is
a prospective, international observational study that recruited ACS patients
undergoing PCI in 2007-08, capturing practice patterns, treatment and res-
sources use over 12 months. Interventional cardiologists collected data from
ACS event to hospital discharge and general practitioners and cardiologists
collected follow-up data.
Results: 483 eligible ACS-PCI patients had mean age 61 (13) years, mean
weight 80 (15) kg, were 18% female, 47% with ST-elevation MI (STEMI) and
53% with unstable angina or non-ST elevation MI (UA/NSTEMI). Follow-up
data up to 12 months are available for 396 (82%) patients. Among patients
who were discharged and had follow-up data, 94% were receving clopidogrel
at time of hospital discharge. Cardiovascular combination therapy was pres-
cribed as follows: aspirin (95%), statins (82%), beta-blockers (82%), ACE
inhibitors/ARBs (68%); each of these treatments was globally maintained over
12 months. Lifestyle therapies increased over 12 months from 12% to 57% for
formal diet program and 11% to 48% for formal exercise program. Over 12
months, on 394 patients, overall clopidogrel use was 94% at 30 days, 80% at
6 months, and 75% at 12 months. Amongst 83 patients who stopped clopido-
grel before 12 months, 48% discontinued during the first three months.
Conclusions: These prospective data showed that after an ACS event 20%
of patients have already dropped out their clopidogrel treatment at 6 months
and 25% at 12 months.
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Background: Inadequate anticoagulation in patients undergoing percuta-
neous coronary Intervention (PCI) is associated with more frequent periproce-
dural ischemic events.
Methods: We evaluated the ability of the bedside Hemonox test to identify
patients with an anti-Xa activity level out of the therapeutic range in 296 unse-
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lected patients undergoing catheterization and/or PCI. Bedside measure of
whole blood Hemonox Clotting Time (CT) and activated Partial Prothrombin
Time (aPTT) were measured at baseline (T1) and 10’ after the IV administra-
tion of enoxaparin (T2) in patients receiving additional enoxaparin and com-
pared to differed plasma chromogenic anti-Xa (AXA) activity measurement.
Results: Median [IQR] values were 0.1 [0.1-0.1] and 0.87 [0.74-1.03] IU/
mL for AXA; 74 [70-81] and 143 [114-206] sec for Hemonox CT, and 44 [39-
50] and 72 [58-93] sec for aPTT at T1 and T2 time points, respectively.
Hemonox CT strongly correlated with Anti-Xa level spearman r=0.81 (95% CI
0.77-0.84, p<0.0001). When comparing a total of 486 values to discriminate
patients with AXA <0.5 IU/mL, the area under the receiver operating curve
(AUC) for Hemonox CT was 0.95 ± 0.01 (95% IC; 0.93-0.97; p<0.0001)
versus 0.89 ± 0.01 (95% IC; 0.86-0.92; p<0.0001) for aPTT. A threshold
Hemonox CT value of 120 sec was associated with a 94.9% (95% CI 91.1-
97.4) sensitivity and a 73.3% (95% IC 67.6-78.5) specificity with a likelihood
ratio = 3.5 to detect patients with inadequate anti-Xa level (<0.5UI/mL). With
this threshold the positive predictive and negative predictive values of
Hemonox CT as a diagnosis test were 73.9% (95% IC 68.7-79.0) and 94.78%
(95% IC 91.8-97.8) respectively.
Conclusion: According to the results of this study Hemonox CT appears to
be a fast and reliable bedside test that could be used to adjust enoxaparin anti-
coagulation in PCI. 
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Background: Percutaneous coronary interventions (PCI) are proposed with
increasing frequency to elderly and very elderly patients (pts) owing to the
high prevalence of coronary disease in this age group. There are limited data
about differences between aged and very aged pts in respect to risk factors, co
morbidities and outcomes after PCI.
Objectives: We sought to define the differences in clinical presentation
and outcomes in different age classes in elderly pts treated by PCI with stent
implantation.
Methods: 1955 pts aged >75 years (62% men, mean age 80.3±3.8 years)
treated by 2072 PCI with 3352 stents implantations were prospectively
included in this study.
Results: There were 936 pts (47.8%) aged 75-80 years, 707 pts (36.2%)
between 81 and 85 years and 312 pts (16.0%) aged >85 years. Elderly and
very elderly pts had less cardiovascular risk factors (hypercholesterolemia:
58% vs 54% vs 45%, p=0.01, diabetes: 36% vs 35% vs 32%, p=0.02, familial
history of ischemic heart disease: 17% vs 12% vs 9.3%, p=0.002) but more
often renal failure at admission (48% vs 65% vs 72% p<0.001). Unstable coro-
nary syndromes as n indications for stenting increased with age (37% vs 44%
vs 51%) p<0.001) as well as lesions concerning left main coronary disease or
bypass grafts (p=0.04). 6-month cardiac mortality rate increased with age
(1.6% vs 2.8% vs 5.2%, p=0.008) as well as cerebral vascular events (0.1% vs
0.8% vs 1.2%, p=0.03) while the rate of non fatal myocardial infarction
remained similar (1.4 % vs 2.0 % vs 2.4%, p=NS).
Conclusion: there are several difference in clinical presentation and 6-
month outcomes in different age classes in elderly pts with ischemic heart
disease treated by PCI with stent implantation with worse results in very
elderly (>85%) pts.
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Background: Primary angioplasty for acute myocardial infarction (PAMI)
proved superior to thrombolysis in many major trials. However, PAMI is
available in only limited number of centers particularly in developing coun-
tries. On the other hand, it was clearly shown that thrombolysis when given
early is associated with a comparable outcome to PAMI. It is however not
known if this can apply to streptokinase (SK) that is the most widely used lytic
agent in developing countries.
Objective: The aim of this study was to assess the in-hospital outcome of
patients given early thrombolysis using SK.
Methods: From the Monastir AMI registry including 1148 patients, 403
received SK therapy. This population was divided into three groups based on
the delay between the onset of symptoms and treatment: Group I: 0 – 3 hours
(n= 208), Group II: 3 – 6 hours (n= 145) and Group III more than 6 hours (n
= 50). Mean age was 60.3 +/- 12 years, 349 (86.6 %) were male. Baseline cha-
racteristics were similar between the three groups.
Results: Clinical reperfusion defined as sedation of chest pain and ST ele-
vation regression for more than 50% from baseline was observed in 75.1 % of
Group I, 58.8% of Group 2 and in 46.8 % of Group 3 pts. ( p < 0.01 ). In
hospital mortality and complications are compared between the three groups
in the table below.
Conclusion: Early thrombolysis (less than 3 hours from chest pain onset)
using streptokinase is associated with a very high percentage of clinical reper-
fusion (75%), a lower rate of heart failure and mortality. These results have
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ROC for Hemonox CT and aPTT to detect Axa<0.5UI/ml
Group I Group II Group III p
Heart failure 31 (14.9%) 37 (25.5%) 18 (36%) 0.001
Ventricular 
fibrillation
8 (3.8%) 10 (6.9%) 2 (4%) 0.407
Ventricular 
tachycardia
6 (2.9%) 10 (6.9%) 4 (8%) 0.133
Pericarditis 10 (4.8%) 7 (4.8%) 4 (8%) 0.636
Death 14 (6.7%) 9 (6.2%) 7 (14%) 0.166
